SEC Form 4 · accession 0000914190-26-000137
Envoy Medical, Inc. · COCH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Potashnick
Officer — CAO & VP of Finance
Period of report
Aug 24, 2026
Accepted (ET)
Aug 26, 2026 · 5:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001840877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | holding | — | — | — | 212,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.746 | Aug 24, 2026 | A | 250,000 | A | — | Aug 24, 2036 | Class A Common Stock | 250,000 | 250,000 | D |
| Stock Option (right to buy)F1 | $0.53 | holding | — | — | — | — | Feb 5, 2036 | Class A Common Stock | 15,000 | 15,000 | D |
| Warrant (right to buy)F3,F4 | $0.40 | holding | — | — | — | — | — | Class A Common Stock | 127,500 | 127,500 | D |
| Warrant (right to buy)F3,F5 | $0.40 | holding | — | — | — | — | — | Class A Common Stock | 212,500 | 212,500 | D |
Explanation of responses
- F1Options to purchase 3,750 shares vest on 2/5/2027, and 11,250 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.
- F2Options to purchase 62,500 shares vest on 8/24/2027, and 187,500 shares vest pro rata on the 24th of each month thereafter for 36 consecutive months.
- F3Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
- F4The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
- F5The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.